1062. Measles Specific Neutralizing Antibody Titers in Various Immunoglobulin Products in Korea
Session: Poster Abstract Session: Herpesviruses, HPV, and Other Viruses
Friday, October 9, 2015
Room: Poster Hall
Background: With the effects of the long-term successful elimination of endemic measles from many countries such as US and Korea, measles antibody concentrations might have decreased in immune globulin (IG) donor populations. From 2012, ACIP revised the recommendation for the use of immunoglobulin (IG) products for measles post-exposure prophylaxis (PEP), including increasing the recommended dose of IGIM for immunocompetent persons and the use of IGIV for severely immunocompromised persons and pregnant. To evaluate whether this recommendation can be adapted to Korea, we analyzed the titers of measles-specific antibodies in IG products available in Korea and compared with those in IG products from other countries.

Methods: We collected 25 lots of intravenous (19 lots from 5 manufacturers), intramuscular (5 lots from 4 manufacturers) and subcutaneous (1 lot) IG products from five countries. Measles specific neutralizing antibody levels of IG products are determined by plaque reduction neutralization test(PRNT).

Results: The measles-specific antibody titers in 25 lots of IG products were 5,449-39,703 mIU/ml. Detailed results are shown in Table 1. According to the calculated trough titer with the formula (http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4317b1-03-TopicII.htm), Korean IGIM products with current potency could be expected to provide a measles antibody concentration of ≥120 mIU/mL for 4-5 days, if administered at the increased dose of 0.5 mL/kg. Korean IGIV products with current potency are sufficient to prevent measles if administered at least 400 mg/kg.

Conclusion: The recent revised ACIP recommendation for the use of IG products for measles PEP can be adapted to those in Korea, too. Continuous monitoring of measles specific antibody titers in various immunoglobulin products is needed.

Table 1. Measles Specific Antibody Titers in Various Immunoglobulin Products from Different Countries

Route

Plasma

source

Manufacturer

(Number of lot)

IgG concentration

(mg/mL)

Ab titer (mIU/ml)

Mean (Range)

IV

Korea

A (10)

B (6)

50

50

 8,440 (4,800~14,000)

10,288 (6,600~14,300)

Japan

C (1)

D (1)

50

50

 5,449

10,384

US

E (1)

50

10,795

IM

Korea

A (2)

165

13,331

Japan

 

F (1)

G (1)

H (1)

150

150

150

31,236

24,528

28,125

SC

Germany

I (1)

200

39,703

Hye-Kyung Cho, M.D., Ph.D.1,2, Dae Sun Jo, M.D., Ph.D.3, Soyoung Lee, M.D., Ph.D.2,4, Han Wool Kim, M.D., Ph.D.2,4, Sung Soon Kim, Ph.D5, Hae Ji Kang, Ph.D.5 and Kyung-Hyo Kim, MD, PhD2,6, (1)Pediatrics, Gachon University, Graduate School of Medicine, Incheon, South Korea, (2)Ctr. for Vaccine Evaluation and Study, Ewha Med. Res. Inst., Sch. of Med., Ewha Womans Univ., Seoul, South Korea, (3)Department of Pediatrics, Chonbuk National University Medical School, Jeonju, South Korea, (4)Pediatrics, Sch. of Med., Ewha Womans Univ., Seoul, South Korea, (5)Division of Respiratory Viruses, Center for Infectious Disease, National Institute of Health, Chungbuk, South Korea, (6)Department of Pediatrics, Sch. of Med., Ewha Womans Univ., Seoul, South Korea

Disclosures:

H. K. Cho, None

D. S. Jo, None

S. Lee, None

H. W. Kim, None

S. S. Kim, None

H. J. Kang, None

K. H. Kim, Ministry of Food and Drug Safety: Grant Investigator , Grant recipient

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.